Successful Protection Against Tularemia in C57BL/6 Mice is Correlated with Expansion of Francisella Tularensis-specific Effector T Cells

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2014 Nov 21

PMID 25410207

Citations 26

Authors

Amanda J Griffin

Deborah D Crane

Tara D Wehrly

Catharine M Bosio

Affiliations

Soon will be listed here.

Abstract

Francisella tularensis is an intracellular, Gram-negative bacterium that causes the fatal disease tularemia. Currently, there are no licensed vaccines for tularemia and the requirements for protection against infection are poorly defined. To identify correlates of vaccine-induced immunity against tularemia, we compared different strains of the live vaccine strain (LVS) for their relative levels of virulence and ability to protect C57BL/6 mice against challenge with virulent F. tularensis strain SchuS4. Successful vaccination, as defined by survival of C57BL/6 mice, was correlated with significantly greater numbers of effector T cells in the spleen and lung. Further, lung cells and splenocytes from fully protected animals were more effective than lung cells and splenocytes from vaccinated but nonimmune animals in limiting intracellular replication of SchuS4 in vitro. Together, our data provide a unique model to compare efficacious vaccines to nonefficacious vaccines, which will enable comprehensive identification of host and bacterial components required for immunization against tularemia.

Citing Articles

Current vaccine strategies and novel approaches to combatting Francisella infection.

Harrell J, Roy C, Gunn J, McLachlan J Vaccine. 2024; 42(9):2171-2180.

PMID: 38461051 PMC: 11095077. DOI: 10.1016/j.vaccine.2024.02.086.

Contribution of Lipid Mediators in Divergent Outcomes following Acute Bacterial and Viral Lung Infections in the Obese Host.

Schwarz B, Roberts L, Bohrnsen E, Jessop F, Wehrly T, Shaia C J Immunol. 2022; 209(7):1323-1334.

PMID: 36002235 PMC: 9529825. DOI: 10.4049/jimmunol.2200162.

Circulating T Cells Are Not Sufficient for Protective Immunity against Virulent .

Roberts L, Wehrly T, Leighton I, Hanley P, Lovaglio J, Smith B J Immunol. 2022; 208(5):1180-1188.

PMID: 35149529 PMC: 8881340. DOI: 10.4049/jimmunol.2100915.

The O-Ag Antibody Response to Francisella Is Distinct in Rodents and Higher Animals and Can Serve as a Correlate of Protection.

Shoudy L, Namjoshi P, Giordano G, Kumar S, Bowling J, Gelhaus C Pathogens. 2021; 10(12).

PMID: 34959601 PMC: 8704338. DOI: 10.3390/pathogens10121646.

A study of innate immune kinetics reveals a role for a chloride transporter in a virulent Francisella tularensis type B strain.

Matz L, Petrosino J Microbiologyopen. 2021; 10(2):e1170.

PMID: 33970545 PMC: 8483402. DOI: 10.1002/mbo3.1170.

References

Crane D, Griffin A, Wehrly T, Bosio C . B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses. J Immunol. 2013; 190(6):2756-66. PMC: 3594638. DOI: 10.4049/jimmunol.1202697. View

Chen W, KuoLee R, Austin J, Shen H, Che Y, Conlan J . Low dose aerosol infection of mice with virulent type A Francisella tularensis induces severe thymus atrophy and CD4+CD8+ thymocyte depletion. Microb Pathog. 2005; 39(5-6):189-96. PMC: 1564440. DOI: 10.1016/j.micpath.2005.08.005. View

Bakshi C, Malik M, Mahawar M, Kirimanjeswara G, Hazlett K, Palmer L . An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine. 2008; 26(41):5276-88. PMC: 2652725. DOI: 10.1016/j.vaccine.2008.07.051. View

EIGELSBACH H, Tulis J, OVERHOLT E, GRIFFITH W . Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine. Proc Soc Exp Biol Med. 1961; 108:732-4. DOI: 10.3181/00379727-108-27049. View

Crane D, Scott D, Bosio C . Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia. PLoS One. 2012; 7(3):e33349. PMC: 3299770. DOI: 10.1371/journal.pone.0033349. View

Conlan J, Shen H, KuoLee R, Zhao X, Chen W . Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma-.... Vaccine. 2005; 23(19):2477-85. DOI: 10.1016/j.vaccine.2004.10.034. View

Anderson R, Crane D, Bosio C . Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs. Vaccine. 2010; 28(40):6562-72. PMC: 2939155. DOI: 10.1016/j.vaccine.2010.07.072. View

Elkins K, Culkin S, Yee D, Winegar R . Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun. 1996; 64(8):3288-93. PMC: 174220. DOI: 10.1128/iai.64.8.3288-3293.1996. View

Twine S, Shen H, Harris G, Chen W, Sjostedt A, Ryden P . BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge.... Vaccine. 2012; 30(24):3634-45. DOI: 10.1016/j.vaccine.2012.03.036. View

10.

Jeong Y, Jeon B, Gu S, Cho S, Shin S, Chang J . Differentiation of antigen-specific T cells with limited functional capacity during Mycobacterium tuberculosis infection. Infect Immun. 2013; 82(1):132-9. PMC: 3911842. DOI: 10.1128/IAI.00480-13. View

11.

Crane D, Ireland R, Alinger J, Small P, Bosio C . Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α. Clin Vaccine Immunol. 2013; 20(10):1531-40. PMC: 3807199. DOI: 10.1128/CVI.00319-13. View

12.

Griffin A, Crane D, Wehrly T, Scott D, Bosio C . Alternative activation of macrophages and induction of arginase are not components of pathogenesis mediated by Francisella species. PLoS One. 2013; 8(12):e82096. PMC: 3855703. DOI: 10.1371/journal.pone.0082096. View

13.

Way S, Thompson L, Lopes J, Hajjar A, Kollmann T, Freitag N . Characterization of flagellin expression and its role in Listeria monocytogenes infection and immunity. Cell Microbiol. 2004; 6(3):235-42. DOI: 10.1046/j.1462-5822.2004.00360.x. View

14.

Ellis J, Oyston P, Green M, Titball R . Tularemia. Clin Microbiol Rev. 2002; 15(4):631-46. PMC: 126859. DOI: 10.1128/CMR.15.4.631-646.2002. View

15.

SASLAW S, EIGELSBACH H, Prior J, Wilson H, CARHART S . Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med. 1961; 107:702-14. DOI: 10.1001/archinte.1961.03620050068007. View

16.

Chase J, Bosio C . The presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo. Infect Immun. 2009; 78(1):154-67. PMC: 2798182. DOI: 10.1128/IAI.00750-09. View

17.

Cowley S, Goldberg M, Ho J, Elkins K . The membrane form of tumor necrosis factor is sufficient to mediate partial innate immunity to Francisella tularensis live vaccine strain. J Infect Dis. 2008; 198(2):284-92. DOI: 10.1086/589620. View

18.

Chen W, Shen H, Webb A, KuoLee R, Conlan J . Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host.... Vaccine. 2003; 21(25-26):3690-700. DOI: 10.1016/s0264-410x(03)00386-4. View

19.

Pechous R, McCarthy T, Mohapatra N, Soni S, Penoske R, Salzman N . A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS One. 2008; 3(6):e2487. PMC: 2429968. DOI: 10.1371/journal.pone.0002487. View

20.

Melillo A, Foreman O, Elkins K . IL-12Rβ2 is critical for survival of primary Francisella tularensis LVS infection. J Leukoc Biol. 2013; 93(5):657-67. PMC: 3629441. DOI: 10.1189/jlb.1012485. View